Clinical Trials Logo

Clinical Trial Summary

Celiac disease is a condition in which the small intestine is damaged by gluten, the storage protein of wheat and similar proteins in barley and rye. The disease can cause different symptoms such as diarrhea, bloating, abdominal pain and weight loss. The majority of patients respond to a gluten-free diet. However some patients (5-30%) have persistent symptoms and are considered to be poor responders to the diet. Bacterial overgrowth in the small intestine accounts for some of the refractory patients.

This study seeks to determine if antibiotic therapy with rifaximin relieves the symptoms of patients who are poorly responsive to a gluten-free diet and whether this impacts their breath test results.


Clinical Trial Description

A symptom questionnaire will be administered at study initiation, 2 weeks and 12 weeks. Patients will undergo a breath test which involves drinking a sugar (lactulose) solution and breathing into a machine. This technique will identify the presence of bacteria in the small intestine. They will be randomly selected to receive either an antibiotic (rifaximin) or placebo three times a day for 10 days to treat their bacterial overgrowth. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01137955
Study type Interventional
Source Columbia University
Contact
Status Completed
Phase N/A
Start date October 2006
Completion date April 2008

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02754609 - Hookworm Therapy for Coeliac Disease Phase 1
Terminated NCT01902368 - Celiac Disease Screening N/A
Completed NCT02472704 - Lymphocytic Enteritis and Suspected Coeliac Disease: Gluten vs Placebo N/A
Completed NCT02312349 - Assessment of Gluten-Free Availability in Elaborated Food Stores in Three Neighbourhoods of Buenos Aires City N/A
Recruiting NCT01172665 - Celiac Disease Database N/A
Completed NCT01100099 - HLA-DQ2-gliadin Tetramer for Diagnosis of Celiac Disease Phase 2/Phase 3
Completed NCT00639444 - Risk of Celiac Disease and Age at Gluten Introduction N/A
Completed NCT00362856 - Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects Phase 2
Not yet recruiting NCT03569007 - Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Treatment of Celiac Disease Phase 3
Completed NCT02244047 - Cytokine Profile in Children With Celiac Disease Phase 1/Phase 2
Active, not recruiting NCT01695681 - Screen-detected Coeliac Disease, a Population Based Study N/A
Active, not recruiting NCT00617838 - Celiac Disease Prevention N/A
Completed NCT00671138 - Inoculating Celiac Disease Patients With the Human Hookworm Necator Americanus: Evaluating Immunity and Gluten-sensitivity Phase 2
Completed NCT00540657 - A Phase II Study of CCX282-B in Patients With Celiac Disease Phase 2
Recruiting NCT03775499 - Probiotic BL NCC 2705 and Gluten Sensitivity N/A
Recruiting NCT03288831 - Changes in Intestinal Permeability 4 Hours After Gluten Challenge N/A
Completed NCT01396213 - A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease Phase 2
Recruiting NCT03136731 - Evidence-based Screening Strategies for Celiac Disease N/A
Completed NCT00386165 - Safety Study of Larazotide Acetate to Treat Celiac Disease. Phase 1
Recruiting NCT03678935 - Effect of FODMAP Restriction on Persistent GI-symptoms in Coeliac Patients N/A